You might know Karen Finerman as a hedge fund manager or as the prettiest Fast Money trader. But did you know despite her conservative demeanor she’s sometimes a barbarian. No, not like that, we mean activist investor.
When a company is being mismanaged, she makes her voice heard by speaking with her money. In fact, she did exactly that two years ago with biotech firm Cyberonics . Despite the promise of a breakthrough, niche product -- a nerve stimulator to treat epilepsy -- the shares never really delivered. Then, adding insult to injury, word surfaced that the CEO at the time was embroiled in an options backdating scandal. So with her 7% stake in hand, she launched a proxy fight: leveraging her rights as a shareholder to elect new board members which included partner Jeffrey Schwarz.Page 1 of 4 | Next Page